Relmada Therapeutics, Inc. (RLMD)
$3.24-3.57%Close
SELLCRISIS · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $340M
- Beta
- 0.45
- P/E (TTM)
- -3.52
- Short % float
- 14.85%
- Days to cover
- 13.0
- SI change
- -7.2%
- 1W
- -0.31%
- 1M
- -27.03%
- vs SPY 1W
- -0.17%
- vs SPY 1M
- -29.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 10
- VALUE
- 6
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-28.5%
REV YoY-
ROE-47.5%
EPS YoY-
ROA-28.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.52
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.76
P/FCF-
EV/EBITDA-5.30
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO29.52
ND/EBITDA-
BETA0.45
Company news
FAQ
- What is LOPJLB’s current signal on RLMD?
- LOPJLB’s latest quantitative signal on Relmada Therapeutics, Inc. (RLMD) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RLMD in?
- Relmada Therapeutics, Inc. (RLMD) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Relmada Therapeutics, Inc. (RLMD) do?
- Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, wh…